Introduction
============

Lung cancer is one of the most common types of malignant carcinoma worldwide and is associated with gradually increasing rates of morbidity and mortality ([@b1-ol-0-0-8723],[@b2-ol-0-0-8723]). Therefore, it is important to establish a timely and accurate method for diagnosing lung cancer in the clinic. Liquid-based cytology (LBC) was listed as one of the differential diagnostic standards for lung cancer by the World Health Organisation in 2004 ([@b3-ol-0-0-8723]). LBC have many advantages, such as a well preserved cellular structure, a reduction in the number of inadequate smears and an even distribution of cells ([@b4-ol-0-0-8723]). Based on these advantages compared with traditional cytological examination, LBC has been widely used in the diagnosis of lung cancer ([@b5-ol-0-0-8723]--[@b7-ol-0-0-8723]). However, as the results of LBC are primarily dependent on the judgement of pathologists, who examine samples with their naked eyes, the possibility of false-negative results may not be excluded. DNA image cytometry (DNA-ICM) has gained attention for its advantages, including objectivity, convenience and a high positive rate, in diagnosing various malignant cancer types. Several studies have explicitly demonstrated the significance of DNA-ICM in the diagnosis of cervical, oesophageal, gastric and oral mucosal cancer ([@b8-ol-0-0-8723]--[@b14-ol-0-0-8723]). The present study aimed to investigate the diagnostic value of DNA-ICM for lung cancer based on a comparison with LBC and pathological biopsy ([Fig. 1](#f1-ol-0-0-8723){ref-type="fig"}).

Materials and methods
=====================

### Common materials

The present study was approved by the Ethics Committee of the First Affiliated Hospital of Chongqing Medical University (Chongqing, China). Written informed consent was obtained from all patients. A total of 600 samples were collected from the Respiratory Department of the First Affiliated Hospital of Chongqing Medical University between August 2015 and November 2015. Among them, 135 samples were excluded from the experimental group due to unsatisfactory results following automatic DNA-ICM, including 120 bronchoalveolar lavage fluid (BALF) samples, 12 pleural effusion samples and 3 fine-needle aspiration (FNA) samples. As a result, a total of 465 samples were included in the experimental group, including 386 BALF samples, 70 samples from cases of pleural effusion and 9 samples from FNA procedures. A total of 315 (67.7%) samples were from male patients and 150 (32.3%) were from female patients, with an age range of 16--83 years (mean age, 58.50±13.11 years). Two methods, LBC and automatic DNA-ICM, were used to evaluate these samples. During the next six months (between August 2015 and May 2016), the pathological results of 120 samples from bronchoscopy, endobronchial ultrasound-guided transbronchial needle aspiration and surgical procedures were also reviewed, with an age range of 33--82 years (mean age, 61±9.69 years). The standard for diagnosis in all cases was the combination of liquid-based cytology and pathology.

### Cytology diagnosis

All materials were provided by LBP Medicine Science and Technology Co., Ltd (Guangzhou, China). All operations were completed at room temperature. Specimens were naturally precipitated for 10--15 min and then centrifuged at 1,610 × g for 5 min at room temperature. The supernatant was removed, and cell preservation solution provided by this company was applied to dilute the cells. The supernatant was removed if red blood cells could be observed in the lower layer, or else the reading result would be disrupted. The cells on the surface of the centrifuge tube were removed and the cell preservation solution was applied to dilute the cells. The final dilution concentration of cells was not specific provided it did not impact on their ability to be analysed. Slices (1.2 mm-thick) of BALF, effusion samples and FNA specimens were prepared, placed in 95% alcohol and fixed for \>30 min. All samples underwent Papanicolaou staining about 5 min at room temperature and were diagnosed by at least two pathologists from The First Affiliated Hospital of Chongqing Medical University (Chongqing, China), all of whom were blinded to the patients\' data. If disagreements existed among the pathologists against results of specific samples, an additional pathologist then confirmed the findings. The results were classified as follows: No evidence of cancer cells; evidence of atypical cells; evidence of severe atypical cells; evidence of suspicious cancer cells; and presence of cancer cells ([@b15-ol-0-0-8723]). No evidence of cancer cells and evidence of atypical cells were regarded as negative, and the remaining categories were considered positive.

### Automated DNA-ICM

The specimens underwent routine centrifugation at 800 × g for 5 min in 35°C environment and the supernatant was discarded. Then, 100 µl of cell dispersant purchased from Motic Electric (Xiamen, China) was added, and under the aforementioned centrifugation conditions, a cell precipitation solution was generated. After the addition of 2.5--3 times the volume of distilled water and agitation, the solution was resuspended. For the slides, 2--3 drops of cell suspension were dropped from 5 cm above the centre of the slide to complete specimen production. Then, all samples underwent Feulgen staining in 35°C environment using a 50% Feulgen stain, for 40--45 min. The nucleases on each slide were scanned using the SPICM-DNA automatic cell picture analysis system provided by Motic (Xiamen) Medical Diagnostic Systems Co., Ltd. (Xiamen, China) and the DNA of the nucleases was measured for standard comparisons with normal cells on the same slide. The DNA content of each cell nucleus was measured and DNA ploidy was recorded as a 'c' value. A DNA ploidy of 2c indicates a normal diploid cell, and 4c indicates a tetraploid cell. The DNA Index (DI) was utilized to present the contents of the cellular DNA, with a normal cellular DI=1 and a DI \>2.5 indicating pathological cells ([@b10-ol-0-0-8723]). DI values of 1 and 2.5 reflected normal and suspicious pathological cells, respectively. The results of DNA-ICM were categorized into three classes: Negative results, cells without DNA aneuploidy; suspicious results, a small number of cells with DNA aneuploidy (DI ≥2.5 for 1--2 cells) and visible cellular abnormal hyperplasia (≥10%); and highly suspicious tumor, visible DNA aneuploidy cells (DI ≥2.5 for ≥3 cells) with a visible aneuploidy cellular summit. No evidence of DNA aneuploidy cells was classified as a negative result, and evidence of suspicious or highly suspicious cells was classified as a positive result ([Fig. 2](#f2-ol-0-0-8723){ref-type="fig"}).

### Statistical analysis

The χ^2^-square test was used for the analysis of DNA-ICM with LBC results. The rank sum test was used to analyze the difference of the maximal DNA quantitation between squamous carcinoma and adenocarcinoma, and also between small cell lung cancer and non-small cell lung cancer. The correlations between tumor site, tumor type, clinical stage and the DNA quantitative maximum value, were analyzed using multivariate correlation analysis. Using a receiver operating characteristic (ROC) curve in order to evaluate the diagnostic accuracy of DNA-ICM with LBC. All statistical analyses were conducted using SPSS 20.0 software (IBM Corp., Armonk, NY, USA). All data is presented as mean ± standard deviation. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Pathological diagnoses of all samples

The results of all pathological diagnosis (LBC and pathology) are illustrated in [Table I](#tI-ol-0-0-8723){ref-type="table"}. Out of the 465 cases, 176 cases were diagnosed as positive by LBC. A total of 289 cases exhibited no evidence of severe atypical cells or tumor cells and were diagnosed as negative by LBC. These results were consistent with the results of the pathological examinations showing 7 cases of squamous carcinomas, 11 cases of adenocarcinomas, 5 cases of small-cell carcinomas, 1 case of poorly differentiated carcinoma, 1 case of non-small cell lung cancer (NSCLC) and 1 unclassifiable tumor type case. The sensitivity of LBC was 87.13% ([Table I](#tI-ol-0-0-8723){ref-type="table"}).

### Pathological diagnosis in BALF samples

Of the 385 BALF samples, 143 cases were diagnosed as positive by LBC. A total of 242 cases were diagnosed as negative by LBC. Based on the pathological biopsy results, 168 cases were diagnosed as positive. The sensitivity of LBC was 85.12% ([Table I](#tI-ol-0-0-8723){ref-type="table"}).

### Pathological diagnosis in pleural effusion samples

Among the 70 pleural effusion samples, 26 cases were diagnosed as positive by LBC and 44 cases were diagnosed as negative. Based on the pathological biopsy results, 27 cases were diagnosed as positive. The sensitivity of LBC was 96.30% ([Table I](#tI-ol-0-0-8723){ref-type="table"}).

### Pathological diagnosis in FNA samples

The results of LBC and pathological examinations were the same, with 2 cases diagnosed as negative by LBC and 7 cases diagnosed as positive. The sensitivity of LBC was 100% ([Table I](#tI-ol-0-0-8723){ref-type="table"}).

### Results of DNA-ICM

The results of DNA-ICM for all types of specimens are shown in [Table II](#tII-ol-0-0-8723){ref-type="table"}. There were 194 cases diagnosed as positive by DNA-ICM and 271 cases diagnosed as negative. There were 49 cases diagnosed as positive by DNA-ICM and negative by LBC, but no pathology results were available. There were 57 cases of false-negative. In 10 cases of positive samples diagnosed by pathological biopsy, the LBC results were negative while the DNA-ICM results were positive.

[Table II](#tII-ol-0-0-8723){ref-type="table"} shows the positive diagnostic rates of DNA-ICM, LBC and the combined approach in specimens from three different tissue types. The sensitivities of LBC and DNA-ICM for BALF samples were 85.12 and 69.04%, respectively, and were significantly different (Χ^2^=12.282; P\<0.05). The sensitivities of LBC and the combined approach for BALF samples were 85.12 and 91.04%, respectively, and were not significantly different (Χ^2^=2.838; P\>0.05). Furthermore, the sensitivities of DNA-ICM for BALF samples in detecting lung squamous carcinoma and lung adenocarcinoma were 71.87 and 62.5%, with no statistically significant difference.

In the positive pleural effusion specimens, the sensitivities of LBC and DNA-ICM were 96.3 and 88.89%, respectively, and were not significantly different (X^2^=1.080; P\>0.05). The sensitivities of LBC and the combined approach were the same, with sensitivities for lung squamous carcinoma, and lung adenocarcinoma of 100 and 91.3%, respectively, with no statistically significant difference (X=0.095; P\>0.05). The sensitivities of the DNA-ICM method for BALF and pleural effusion samples were 69.04 and 88.89%, respectively, and were not significantly different (X^2^=4.522; P\>0.05). The number of lung biopsy specimens was too small for a separate analysis.

The total results of DNA-ICM, LBC and the combined approach for all tumor types in all specimens are shown in [Table I](#tI-ol-0-0-8723){ref-type="table"}. In positive specimens, the sensitivities of LBC and DNA-ICM were 87.13 and 71.78%, respectively, with a statistically significant difference (X^2^=14.572; P\<0.05). No statistically significant difference was observed in the positive diagnostic rates between LBC and the combined approach (X^2^=2.657; P\>0.05). The differences in the positive diagnostic rates of DNA-ICM for squamous carcinoma and adenocarcinoma were not statistically significant (X^2^=0.80; P\>0.05).

Overall, 202 cases of lung cancer were identified by cytology and pathology. In these cases, DNA-ICM has certain missed rates, whereby 19/69 cases of squamous cell carcinoma and 24/81 cases of adenocarcinoma were missed. The positive diagnosis rate of DNA-ICM in squamous cell carcinoma and adenocarcinoma cell carcinoma was not statistically significant (P\>0.05). In addition, 10/35 cases of small cell lung cancer (SCLC) were missed, 46/167 cases of non-small cell lung cancer (NSCLC, all types of lung cancer outside of SCLC) were missed. Between the positive diagnosis rate of SCLC and NSCLC, there was no significant difference (P\>0.05) ([Table I](#tI-ol-0-0-8723){ref-type="table"}).

[Table III](#tIII-ol-0-0-8723){ref-type="table"} showed the results of tumor staging, tumor location, and the type. Association between the maximum value of DNA (DNAmax) and tumor staging, tumor location, and tumor type. Of the 202 lung cancer cases, due to economic factors, clear tumor staging was achieved in 123 cases by relevant examinations, including 97 cases of NSCLC of stages I to IV (I, 8 cases; II, 4 cases; III, 23 cases; IV, 62 cases), with the tumor site categorized as central (48 cases) or peripheral (49 cases). There were 26 cases of small cell lung cancer (SCLC), which were divided into extensive stage (19 cases) and limited period (7 cases), with the tumor site categorized as central (20 cases) or peripheral (6 cases). The correlation coefficient between DNAmax and tumor stage was 0.305 (P=0.002), which was positively correlated with NSCLC, but there was no significant correlation between DNAmax and tumor type or tumor location. In SCLC cases, DNAmax, tumor staging and tumor site were not significantly correlated.

The difference in DNAmax between squamous cell carcinoma and adenocarcinoma was analysed by the rank sum test, and was not statistically significant (P=0.054). DNAmax values in SCLC and NSCLC were analysed, and the difference was not statistically significant (P=0.359).

### ROC curves for LBC and DNA-ICM

A total of 202 patients diagnosed with lung cancer, including 26 LBC negative cases and 57 DNA-ICM negative cases. Among the 263 cases of pathologically undiagnosed lung cancers, there were 49 abnormal cases suggested by DNA-ICM. Then the ROC curves were drew according to the results of the test. The areas under the ROC curves of LBC and DNA-ICM were 0.936 and 0.766, respectively ([Fig. 3](#f3-ol-0-0-8723){ref-type="fig"}), with significant difference (P\<0.05). It can be indicated that LBC is the optimal method to diagnose lung cancer, seconded by DNA-ICM method.

Discussion
==========

DNA is the foundation of cell growth, differentiation and reproduction. It exists in a diploid state in the normal body and becomes tetraploid when mitosis begins. However, when a cell undergoes carcinogenesis, genes go through various changes, including mutation, recombination, deficiency, fusion and amplification, resulting in increased cellular DNA content. Therefore, determining the DNA content of target cells relative to normal cells as standard controls may aid in diagnosing an early-stage tumor ([@b5-ol-0-0-8723],[@b6-ol-0-0-8723]). DNA quantitative analysis is a method that maybe mastered in a short time period, with the characteristics of objectivity, quickness, independence and effectiveness ([@b7-ol-0-0-8723]--[@b10-ol-0-0-8723]). DNA-ICM has been applied in research on cervical, oesophageal and oral mucosal cancer, and has been gradually implemented into the clinic, but it has not been used for diagnosing lung carcinoma as of yet ([@b11-ol-0-0-8723]--[@b14-ol-0-0-8723]).

Histopathology has long been regarded as the gold standard for detecting cancer ([@b3-ol-0-0-8723]). LBC is also a well-known diagnostic standard that has been used for the clinical diagnosis of lung carcinoma ([@b16-ol-0-0-8723]). DNA-ICM and LBC require a wait time of \<6 h ([@b17-ol-0-0-8723]) and are priced similarly at \~500 RMB. However, the DNA detection method is relatively simple and the training of specialized staff requires a few weeks. LBC diagnoses rely on the judgement of pathologists who require several years of specialized training ([@b9-ol-0-0-8723]). However, DNA-ICM can only judge the abnormal cells, but it cannot identify the types of tumor cell, including squamous carcinoma, adenocarcinoma and SCLC.

In the present study, LBC and DNA-LBC results were available for all cases, and histopathology results were available for 120 cases. Therefore, the present study aimed to analyse the diagnostic value of DNA-ICM in the diagnosis of lung carcinoma compared with the combined approach of LBC and histopathology.

Certain malignant tumors, including lung cancer, exhibit diploid DNA, whereas certain benign cases present heteroploid cells ([@b18-ol-0-0-8723]--[@b21-ol-0-0-8723]). Rijken *et al* ([@b19-ol-0-0-8723]) reported that 25% of malignant tumors are diploid, including in lung, oral, breast and bladder cancer ([@b19-ol-0-0-8723],[@b21-ol-0-0-8723]--[@b25-ol-0-0-8723]). In the current study, 202 confirmed lung cancer cases were identified. Correlation analysis demonstrated that DNAmax and tumor staging were positively correlated in NSCLC cases, possibly because the tumor was more aggressive. This result is similar to the findings of a study by Kasprzyk *et al* ([@b26-ol-0-0-8723]).

The DNA analysis results revealed that the following cases were not heteroploid: 52 cases with BALF samples; 3 cases with pleural effusion samples; and 2 cases with FNA samples. Evident heteroploid cells were observed in 49 cases, but no pathological evidence of lung cancer was observed.

In the 57 false-negative cases from the DNA-ICM results, one case evaluated using a pleural effusion sample was diagnosed as small-cell carcinoma; however, this patient is currently being treated with chemotherapy. Chemotherapy may affect tumor ploidy ([@b27-ol-0-0-8723]), which can affect DNA analysis results. Various studies have also reported that no heteroploidy is evident in certain DNA samples of malignant tumors with different ratios of false-negative cases ([@b19-ol-0-0-8723],[@b21-ol-0-0-8723]--[@b23-ol-0-0-8723]). There are also reports indicating that in certain cells, due to similar appearances, DNA analysis results may demonstrate heteroploidy and diploidy because of their heterogenicity or because diploids are able to gradually become heteroploids during tumor development ([@b22-ol-0-0-8723],[@b28-ol-0-0-8723],[@b29-ol-0-0-8723]). However, the study of Bisht *et al* ([@b23-ol-0-0-8723]) reported that certain minor changes and chromosomal abnormalities cannot be detected by DNA analysis. When the number of diploid cells predominates over that of heteroploid cells, DNA analysis may still not detect abnormal cells ([@b21-ol-0-0-8723],[@b30-ol-0-0-8723]). In addition, DNA quantitative analysis does not reveal heteroploid cells if the tumor chromosomes maintain a balance between loss and replication ([@b18-ol-0-0-8723],[@b31-ol-0-0-8723]). Therefore, so-called false-negative results may not truly be false-negative under the circumstance that tumor characteristics cannot be detected by DNA-ICM. In the present study, the majority of the false-negative results came from BALF samples as there is no specific standard for BALF retrieval, and samples are not typically collected by the same person, leading to differences in surgery technique. All these factors may influence sample quality. In addition, the effects of sampling errors and poor sample handling could not be excluded ([@b14-ol-0-0-8723]), which may lead to real false-negative results.

A total of 49 cases, included routine follow-up visit data. DNA analysis revealed abnormalities, but none of these cases were diagnosed as lung cancer. Ten patients showed a high possibility of lung cancer based on their medical histories, tumor biomarker results and imaging results. However, specific pathological evidence for their diagnoses was not obtained, as the patients refused to undergo tissue biopsy. Furthermore, the remaining 39 cases, 3 cases of pulmonary tuberculosis, 19 cases of pulmonary infection, 6 cases of pulmonary benign changes, and 11 undiagnosed cases, demonstrated heteroploidy even though they were not diagnosed as lung cancer, possibly because DNA-ICM is able to diagnose malignant tumors 1--15 months before histology can ([@b32-ol-0-0-8723],[@b33-ol-0-0-8723]). Furthermore, a previous study reported the possibility of false-positive results caused by hyperplasia when cells are affected by bacteria, viruses, fungus or certain drugs ([@b10-ol-0-0-8723]). Heteroploidy may also appear when cells are damaged during the process of obtaining samples. The aforementioned factors may account for the appearance of false-positive results to a certain extent. The present cohort of patients needs to be followed to determine whether lung cancer or another disease maybe diagnosed.

The present results suggest that the diagnostic value of DNA-ICM may not be superior to LBC, according to the positive diagnostic rates and ROC curves. In pleural effusion samples, the results of DNA-ICM were the same as those of pathology, but the positive diagnostic rate of DNA-ICM was significantly lower compared with that of LBC in BALF samples, potentially due to the aforementioned reasons. In 10 BALF samples, cancer cells were not detected by LBC, while DNA-ICM revealed heteroploid cells in tissue biopsies, thus confirming the presence of lung cancer. This may be explained by the fact that LBC results are interpreted according to a physicians\' visual evaluation, which may lead to subjective outcomes and missed diagnoses, but DNA-ICM is able to identify precancerous lesions that are overlooked in visual inspection. Therefore, LBC combined with DNA-ICM improves the positive diagnostic rate, even though there is no significant difference when compared with LBC alone. In addition, 16 cases were identified as negative by LBC and DNA-ICM, but the tissue biopsies revealed lung cancer. Therefore, tissue biopsies are still necessary to diagnose lung cancer and to avoid missed diagnoses, even when LBC and DNA-ICM are combined.

DNA-ICM has been widely used in the diagnosis of the cervical cancer, with a threshold of \>5c for DNA content and DI ≥3 for cell amount ([@b11-ol-0-0-8723]). Furthermore, Bradley *et al* ([@b13-ol-0-0-8723]) reported that the amount of DNA is \>4.6C and the cell amount is ≥3 in oral cancer, which is regarded as the positive threshold. Tao *et al* ([@b34-ol-0-0-8723]) reported that a DNA content of \>2.5C and cell amount of ≥4 had the highest diagnostic value in BALF samples ([@b34-ol-0-0-8723]). Therefore, different types of malignant tumors have various thresholds in DNA-ICM. However, the diagnostic threshold for lung cancer has not yet been standardized. In the current study, a diagnostic threshold of \>5C for DNA content and ≥3 for cell amount was chosen, and positive results were determined when the DNA-ICM results suggested the presence of cancer. The appearance of false-positive and false-negative results in the present study may be associated with the difference in the diagnostic threshold. In the present study, cases with false-negative results accounted for majority of the BALF samples, possibly because different types of samples require different diagnostic thresholds; however, more samples are required to determine the reason behind this finding.

Tao *et al* ([@b34-ol-0-0-8723]) reported that the positive diagnostic rate for SCLC is significantly higher compared with that for pulmonary adenocarcinoma in BALF samples. Nevertheless, in the results of the present study, no statistically significant difference was identified between these two types of cancer in BALF and pleural effusion samples, which may be due to the diagnostic threshold chosen, and sampling errors. Therefore, more samples must be collected to determine the optimal diagnostic threshold.

Certain researchers suggest that due to tumor heterogeneity, it is necessary to perform DNA-ICM on five independent samples for every case to identify true diploid cells and decrease the likelihood of false-negative results ([@b22-ol-0-0-8723],[@b29-ol-0-0-8723]). However, this would greatly increase examination costs. Additionally, DNA-ICM may only determine differences in DNA amounts rather than the exact pathological types of cancer. Therefore, further examinations with cytology or tissue biopsy are still required to define the cancer type. The clinical application of DNA-ICM is indeed restricted in this way. However, DNA-ICM may serve as a valuable method when utilized appropriately.

Automatic DNA-ICM has medium diagnostic value in lung cancer. The positive diagnostic rate in lung cancer maybe improved to a certain extent when DNA-ICM is combined with LBC, demonstrating a possible supplementary role. DNAmax was positively correlated with tumor stage in NSCLC, but DNA-ICM is not able to identify the type of tumor, and may generate false-positive and false-negative results. Therefore, DNA-ICM alone cannot be recommended for lung cancer screening. The threshold value of DNA-ICM for lung specimens is not yet clear and requires further study. When the results of LBC and DNA-ICM are conflicting, the patient should be thoroughly evaluated.
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![Flowchart of the research plan. BALF, bronchoalveolar lavage fluid; FNA, fine needle aspiration; LBC, liquid-based cytology; DNA-ICM, DNA image cytometry; ROC, receiver operating characteristic.](ol-16-01-0915-g00){#f1-ol-0-0-8723}

![Difference between the results of the DNA-ICM. Representative (A1 and A2) negative; (B1 and B2) suspicious of tumor; and (C1 and C2) highly suspicious of tumor results. The leftimages illustrate the DNA index of every nucleus of different cells in the specimens. The right images illustrate the distribution of the cells in the specimens. Red represents pathological cells, orange represents hyperplastic cells, green represents normal cells, and blue and purple represent lymphocytes and neutrophils cells. The block diagram symbol in the images on the right represents the position of the cells and is representative of the selected cells. System scan cell under magnification, ×20.](ol-16-01-0915-g01){#f2-ol-0-0-8723}

![ROC curves of the LBC and DNA-ICM. ROC curves for (A) liquid-based cytology and (B) DNA image cytometry. ROC, receiver operating characteristic; LBC, liquid-based cytology; DNA-ICM, DNA image cytometry](ol-16-01-0915-g02){#f3-ol-0-0-8723}

###### 

Results of DNA-ICM, LBC and combined diagnosis in the three specimens of different tissue type.

                                                           DNA-ICM   Cytology   Combined diagnosis                 
  ------------------ ------------------------------- ----- --------- ---------- -------------------- ------- ----- -------
  BALF                                                                                                             
                     Squamous carcinoma              64    46        71.87      57                   89.06   60    93.75
                     Adenocarcinoma                  56    35        62.5       45                   80.36   49    87.5
                     Small cell carcinoma            32    23        71.88      28                   87.5    30    93.75
                     Non-small cell lung cancer      9     6         66.67      8                    99.89   8     99.89
                     Poor differentiated carcinoma   6     6         100        5                    83.33   6     100
                     Unclassifiable                  1     0         0          0                    0       0     0
                     Total                           168   116       69.04      143                  85.12   153   91.07
  Pleural effusion                                                                                                 
                     Squamous carcinoma              1     1         100        1                    100     1     100
                     Adenocarcinoma                  23    21        91.3       23                   100     23    100
                     Small cell carcinoma            2     0         0          1                    50      1     50
                     Poor differentiated carcinoma   1     1         100        1                    100     1     100
                     Total                           27    24        88.89      26                   96.3    26    96.3
  FNA                                                                                                              
                     Squamous carcinoma              4     3         75         4                    100     4     100
                     Adenocarcinoma                  2     1         50         2                    100     2     100
                     Small cell carcinoma            1     1         100        1                    100     1     100
                     Total                           7     5         71.42      7                    100     7     100
  Overall                                                                                                          
                     Squamous carcinoma              69    50        72.46      62                   89.86   65    94.2
                     Adenocarcinoma                  81    57        70.37      70                   86.42   74    91.36
  NSCLC              Poor differentiated carcinoma   7     7         100        6                    85.71   7     100
                     Unclassifiable                  1     0         0          0                    0       0     0
                     Non-small cell lung cancer      9     6         66.67      8                    88.89   8     88.89
  SCLC               Small cell carcinoma            35    25        71.42      30                   85.71   32    91.43
                     Total                           202   145       71.78      176                  87.13   186   92.08

BALF, bronchoalveolar lavage fluid; DNA-ICM, DNA image cytometry-FNA, fine-needle aspiration.

###### 

Results of DNA-ICM and pathological diagnosis for all type of specimens.

                                Pathology                  
  ------------------ ---------- ----------- ------ ------- -------
  Overall                                                  
                     Positive   145           49   71.78   81.37
                     Negative   57          214            
  BALF                                                     
                     Positive   116           43   69.05   80.28
                     Negative   52          175            
  Pleural effusion                                         
                     Positive   24            6    88.89   86.05
                     Negative   3             37           
  FNA                                                      
                     Positive   5             0    71.43   100
                     Negative   2             2            

BALF, bronchoalveolar lavage fluid; DNA-ICM, DNA image cytometry; FNA, fine-needle aspiration.

###### 

The result of tumor staging, tumor location, and the type.

                      NSCLC            
  ------------------- ------- ---- --- ----
  Stage                                
    I                 1       7    0   
    II                2       0    2   
    III               17      3    3   
    IV                22      36   4   
    Extensive stage                    19
    Limited period                     7
  Location                             
    Central           25      18   5   20
    Peripheral        16      28   5   6

NSCLC, non small cell lung cancer; SCLC, small cell lung cancer.
